MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
3.960
-0.010
-0.25%
Opening 10:18 08/17 EDT
OPEN
3.960
PREV CLOSE
3.970
HIGH
3.963
LOW
3.930
VOLUME
35.55K
TURNOVER
--
52 WEEK HIGH
7.82
52 WEEK LOW
2.970
MARKET CAP
234.02M
P/E (TTM)
-2.9260
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TARA last week (0810-0814)?
Weekly Report · 4h ago
Protara: Strategic Trial Redesign and Strong TARA-002 Profile Support Buy Rating with Unchanged $27 Price Target
TipRanks · 5d ago
Protara Therapeutics: Advancing Pipeline and Strong Cash Runway Underpin Boris Peaker’s Buy Rating and $25 Price Target
TipRanks · 5d ago
Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26
TipRanks · 5d ago
Protara Sets Multiple Clinical Catalysts For TARA-002; BLA Submission Targeted For 2H27
NASDAQ · 5d ago
Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
Benzinga · 6d ago
Press Release: Protara Therapeutics Announces -2-
Dow Jones · 6d ago
Press Release: Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Dow Jones · 6d ago
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.